Phase 3
AbbVie, a research─based global biopharmaceutical company, presented long─term data from a post─hoc analysis, further supporting the sustained clinical benefit of fixed duration treatment with Venclexta/Venclyxto.
Voor andere berichten over phase III berichten, KLIK HIER!